Oric(US:ORIC) Globenewswire·2025-11-13 21:10Core Insights - ORIC Pharmaceuticals announced the completion of the dose exploration portion of the ORIC-944 Phase 1b clinical trial, demonstrating potential best-in-class efficacy and safety [1][2] - The company appointed Kevin Brodbeck, PhD, as Chief Technical Officer to support the transition to late-stage development [1] - ORIC has approximately $413 million in cash and investments, expected to fund operations into the second half of 2028 [1][3] - Anticipated primary endpoint readouts from the first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) are expected in 2026 [1][2] Clinical Development Updates - ORIC-944 is a potent allosteric inhibitor of PRC2, with provisional recommended Phase 2 doses selected for testing in combination with darolutamide and apalutamide [3] - Preliminary data from the Phase 1b trial showed significant PSA responses, with 55% of patients achieving a PSA50 response and 20% achieving a PSA90 response [3] - ctDNA analysis indicated that 76% of patients achieved over 50% reduction, with 59% achieving ctDNA clearance, surpassing previous standard care results [3] - Safety profiles for both combination regimens were compatible with long-term dosing, with most adverse events being Grade 1 or 2 [3] Financial Performance - For Q3 2025, R&D expenses were $28.8 million, a decrease from $31.2 million in Q3 2024, attributed to lower drug manufacturing costs [7][9] - General and administrative expenses increased to $7.9 million for Q3 2025, compared to $7.1 million in Q3 2024 [8][9] - The net loss for Q3 2025 was $32.6 million, slightly improved from a loss of $34.6 million in Q3 2024 [15] Upcoming Milestones - ORIC anticipates data milestones for ORIC-944 and enozertinib, with combination dose optimization data expected in Q1 2026 and various data presentations scheduled for December 2025 and mid-2026 [6][8]